Thomson Reuters Cortellis Data Fusion Addresses Big Data Challenges by Speeding Access to Critical Pharmaceutical Content
New solution leverages linked data technologies to power the discovery of new scientific and strategic insights
The
“Cortellis Data Fusion gives us the ability to tie together information about entities like diseases and genes and the connections between them. We can do this from Cortellis data, from third party data, from a client's internal data or from all of these at the same time. Our analytics enable the client to then explore these connections and identify unexpected associations, leading to new discoveries",” said Chris Bouton, general manager, Thomson Reuters Life Sciences. “Driving novel insights for our clients is at the very core of our mission and these technologies help to enable that.”
The faster and deeper insight from Cortellis Data Fusion is possible because content is parsed into manageable, actionable Little Data. There are inherent, intuitive data analytic links that enable users to discover unexpected associations, generate hypotheses and share novel ideas. The solution also employs enterprise information security architecture ensuring proprietary data and analyses remain safe.
Opportunities created by Cortellis Data Fusion are a result of the recent acquisition by Thomson Reuters of
Learn more about
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025